- Home
- ACRV vs NMS Comparison
ACRV vs NMS Comparison
Compare ACRV & NMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRV | NMS |
|---|---|---|
| Founded | 2018 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.2M | 78.5M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACRV | NMS |
|---|---|---|
| Price | $1.86 | $12.30 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $11.67 | N/A |
| AVG Volume (30 Days) | ★ 319.7K | 9.4K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.11% |
| EPS Growth | ★ 15.13 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $568.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.20 | $11.07 |
| 52 Week High | $3.56 | $12.49 |
Technical Indicators
Market Signals| Indicator | ACRV | NMS |
|---|---|---|
| Relative Strength Index (RSI) | 65.54 | 58.15 |
| Support Level | $1.73 | $11.90 |
| Resistance Level | $2.02 | $12.46 |
| Average True Range (ATR) | 0.10 | 0.13 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 97.44 | 66.45 |
Price Performance
Historical ComparisonAbout ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.